KRAS, BRAF, PIK3CA mutation frequency of radical prostatectomy samples and review of the literature

Basit Öğe Kaydı
dc.authoridGamsizkan, Mehmet/0000-0001-9942-4898
dc.authoridKantarcioglu Coskun, Sinem/0000-0002-8133-8665
dc.contributor.authorBahcivan, Atike
dc.contributor.authorGamsizkan, Mehmet
dc.contributor.authorCoskun, Sinem Kantarcioglu
dc.contributor.authorCangur, Sengul
dc.contributor.authorYuksel, Alpaslan
dc.contributor.authorCeyhan, Aysegul
dc.contributor.authorOnal, Binnur
dc.date.accessioned2021-12-01T18:47:25Z
dc.date.available2021-12-01T18:47:25Z
dc.date.issued2021
dc.department[Belirlenecek]en_US
dc.description.abstractObjective The molecular basis of prostate cancer is highly heterogeneous. Our study aimed to perform the mutation analysis of KRAS, BRAF, PIK3CA, and immunohistochemical (IHC) evaluation of EGFR, HER2, p16, and PTEN to demonstrate new areas for targeted therapies. Methods A total of 24 prostatectomy samples diagnosed with adenocarcinoma were analyzed by microarray hybridization. Also, these samples were IHC stained for EGFR, HER2, P16, and PTEN. The cases were divided into two groups based on low and high Gleason scores. All findings were compared with the clinicopathological parameters of the patients. Results While KRAS mutation was in 3/24 (12.5%) of our cases, BRAF and PIK3CA mutations were not detected. There was no significant difference between the groups in terms of KRAS mutation frequency. HER2 was immunohistochemically negative in all samples. There was no correlation between EGFR, P16 immunopositivity, and clinicopathological features. Conclusion KRAS mutation frequency is similar to those in Asian populations. BRAF and PIK3CA mutation frequencies have been reported in the literature in the range of 0-15% and 0-10.4%, respectively, consistent with our study findings. HER2 immunoexpression is a controversial issue in the literature. EGFR and p16 expressions may not correlate with the stage.en_US
dc.identifier.doi10.1080/13685538.2021.1901274
dc.identifier.endpage1641en_US
dc.identifier.issn1368-5538
dc.identifier.issn1473-0790
dc.identifier.issue5en_US
dc.identifier.pmid33878842en_US
dc.identifier.scopus2-s2.0-85104773618en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage1627en_US
dc.identifier.urihttps://doi.org/10.1080/13685538.2021.1901274
dc.identifier.urihttps://hdl.handle.net/20.500.12684/10264
dc.identifier.volume23en_US
dc.identifier.wosWOS:000641856000186en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofAging Maleen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectKRASen_US
dc.subjectBRAFen_US
dc.subjectPIK3CAen_US
dc.subjectmutationen_US
dc.subjectprostate canceren_US
dc.subjectGrowth-Factor Receptoren_US
dc.subjectRas Oncogene Mutationsen_US
dc.subjectGene-Mutationsen_US
dc.subjectProstatic Adenocarcinomaen_US
dc.subjectAndrogen-Independenceen_US
dc.subjectMolecular Alterationsen_US
dc.subjectClinical-Significanceen_US
dc.subjectHer-2/Neu Expressionen_US
dc.subjectPathway Alterationsen_US
dc.subjectPi3K Pathwayen_US
dc.titleKRAS, BRAF, PIK3CA mutation frequency of radical prostatectomy samples and review of the literatureen_US
dc.typeReview Articleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
10264.pdf
Boyut:
2.39 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu